Migration to the U.S. Nasdaq stock market: Read the Offer Document, the Form S-4 Registration Statement and other documents.
Allarity Therapeutics is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Cambridge, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.
Our Pipeline
Our Platform
Our DRP® Technology is a first-in-class, highly validated diagnostic platform that models human tumor biology and can help predict whether a cancer patient will respond or not to a particular drug
Publications
Results from our DRP® platform have been published in numerous peer-reviewed scientific journals, highlighting the predictive capabilities of our proprietary approach to precision medicine.
News
Events
TBA
The DRP® Platform
No two people are the same. Neither are their cancers. DRP® technology is a unique and best-in-class proprietary diagnostic platform built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types, and refined with actual gene expression data from more than 3,000 patient tumors"We are building a personalized medicine company developing new therapeutics for unmet needs in the treatment of human cancers through use of our world-class companion diagnostics platform."
Steve Carchedi, CEO
